Skin Pharmacology and Physiology · 2017 · 64 citations · 36 references
PharmacyDermatologyPharmaceuticsDrug DeliveryNanomaterialsNanoparticle Drug DeliveryDrug EncapsulationNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsNanoparticle DesignNanoparticle FormulationsDrug Delivery NanocarriersEmulsification-solvent DiffusionEncapsulation EfficiencyFinasteride TherapyNanocarrier Encapsulation EfficiencyNanoparticlesPolymeric Nanoparticle EncapsulationPolymeric Nanoparticle Formulation
BACKGROUND/AIMS: Androgenetic alopecia is an extremely common dermatological disorder affecting both men and women. Oral finasteride (FNS), a synthetic 4-aza-3-oxosteroid compound with poor aqueous solubility, blocks the peripheral conversion of testosterone to dihydrotestosterone (DHT) in a significant reduction in DHT concentration, achieving satisfactory results in alopecia treatment. However, its oral intake generally causes severe side effects. Considering that there is currently no scientifically proven treatment, new drug delivery systems able to improve alopecia therapy are urgently required. METHODS: In this study, polymeric nanoparticles have been proposed as a new carrier for topical delivery of FNS in hair follicles. RESULTS AND CONCLUSIONS: Polymeric nanoparticles, prepared by using a modified method of the emulsification/solvent diffusion, showed a mean particle size around 300 nm, which may be sufficient for reaching the dermis and hair follicles and negative zeta potential values. Scanning electron microscope measurements showed that all the polymeric nanoparticles exhibited a spherical shape and a smooth surface regardless of their composition. A high encapsulation efficiency was achieved for FNS (79.49 ± 0.47%). In vitro release assays in physiological conditions demonstrated that nanoparticles yielded a prolonged release of FNS for 3 h. Skin assays through an in vitro permeation study demonstrated that nanoparticles had low levels of penetration of FNS, improving its time residence onto the skin. All excipients used in nanoparticle composition and in 3 different vehicles were safe. These results suggest that the proposed novel formulation presents several good characteristics indicating its suitability for dermal delivery of FNS for alopecia treatment.
36
Alet van Tonder, Annie Joubert, Duncan Cromarty · BMC Research Notes · 2015 · 493 citations · Full text
Hideki Murakami, Masao Kobayashi, Hirofumi Takeuchi et al. · International Journal of Pharmaceutics · 1999 · 398 citations · Full text